Journal
CLINICAL INFECTIOUS DISEASES
Volume 75, Issue 2, Pages 330-333Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab1028
Keywords
beta-D-glucan; intravenous immunoglobulines; therapeutic antibodies; false-positive; onto-hematology
Categories
Funding
- Swiss National Science Foundation [31CA30_196036, 33IC30_179636, 314730_192616]
- Leenaards Foundation
- Santos-Suarez Foundation
- Promex Stiftung fur die Forschung (Carigest SA)
- Carigest
- Swiss National Science Foundation (SNF) [31CA30_196036, 33IC30_179636, 314730_192616] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Immunoglobulins and therapeutic antibody preparations are linked to a high rate of false-positive BDG tests in hematological patients. The benefits of BDG monitoring need to be balanced against the risk of unnecessary investigations and costs resulting from false-positive tests in this population.
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-beta-D-glucan (BDG) tests in onto-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
